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ABSTRACT A prevalence survey on hepatitis B and C infections was carried out to obtain national estimates and 
assess epidemiological dynamics and underlying risk factors. Overall prevalence of hepatitis B surface antigen 
(HBsAg) and anti-hepatitis C virus (HCV) of 2.5% and 4.8%, respectively, reflected a combined infection rate of 
7.6% in the general population, consistent with an ongoing high burden of chronic liver disease (CLD). There was 
significant association of these viral infections with a range of risk factors led by reuse of syringes. These findings 
validate currently implemented strategies by the national programme for the control of hepatitis viral infections, 
including universal vaccination of newborns and high-risk groups, support of auto-disable syringes, promotion 
of infection control and patient safety, public health education, and management of needy CLD patients as a 
poverty-reduction health intervention.  
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ةحفاكلماو ةياقولا تاءارجإ نم ديزلم وعدت ينطو حسم جئاتن :ناتسكاب في سيو بي سيويرفلا دبكلا باهتلا راشتنا تلادعم
يديرفآ ديشرلا نوراه ،لماع زاجعإ ديس ،ةعجم ديشر ، دوممح هّلب فيلخ ،شييرق اهم
 ،ةيئابولا تايكيمانيدلا ميـيقتلو ،ةينطولا تاريدقتلا ةفرعلم سيو بي دبكلا باهتلا سويرفب ىودعلا راشتنا لدعلم ًاحسم نوثحابلا ىرجأ :ةـصلالخا
 لعيج امم ،%4.8 سي دبكلا باهتللاو ،%2.5 بي دبكلا باهتللال يحطسلا دضتسملل لياجملإا راشتنلاا لدعم نأ اودجوو .ةنيفدلا راطتخلاا لماوعو
 ًايئاصحإ هب دَتْعُي طبارت كانه ناك دقو .نمزلما دبكلا ضرلم عافترلاا لصاوتلما ءبعلا عم ىشماتي ام وهو ،%7.6 ناكسلا ةماع في ةكترشلما ىودعلا لدعم
 يتلا  تايجيتارـتسلاا ةحص جئاتنلا  هذه د ِّكؤتو .نقاحملل  رركتلما  لماعتسلاا اهسأر لىعو ،راطتخلاا لماوع نم فيط عم هذه ىودعلا  تلاالح
 راطتخلال ةضرعلما تاعومجلماو نادلولا ميعطت لىع لمتشت يتلاو ،دبكلا باهتلا سويرفب ىودعلا ةحفاكلم ةينطولا جمابرلا ضرالحا تقولا في اهذفنت
 باهتلاب ضىرلما يربدتو ،سانلا ةماعل يحصلا فيقثتلاو ،ضىرلما ةملاسو ىودعلا ةحفاكم زيزعتو ،لطعتلا ةيتاذلا نقاحلما مادختسا معدو ،عفترلما
.رقفلا ةأطو فيفختل ةيحصلا تلاخدتلا نم كلذ رابتعاب ،ينجاتحلما نمزلما دبكلا
Prevalence of hepatitis B and C viral infections in 
Pakistan: findings of a national survey appealing for 
effective prevention and control measures
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Prévalence des infections virales de l’hépatite B et de l’hépatite C au Pakistan : résultats d’une enquête 
nationale appelant à des mesures de lutte efficaces
RÉSUMÉ Une enquête de prévalence sur les infections par les virus de l’hépatite B et de l’hépatite C a été 
réalisée afin d’obtenir des estimations nationales et d’évaluer la dynamique épidémiologique et les facteurs 
de risque sous-jacents. La prévalence globale de l’antigène de surface du virus de l’hépatite B et celle des 
anticorps antivirus de l’hépatite C étaient de 2,5 % et 4,8 % respectivement, reflétant un taux global d’infection 
de 7,6 % dans la population générale, ce qui est cohérent avec la charge actuelle élevée d’affections hépatiques 
chroniques. Une association importante de ces infections virales avec de nombreux facteurs de risque liés à la 
réutilisation des seringues a été observée. Ces résultats attestent du bien-fondé des stratégies du programme 
national de lutte contre les infections par le virus de l’hépatite, à savoir : vaccination universelle des nouveau-nés 
et des groupes à haut risque, soutien à l’utilisation de seringues autobloquantes, promotion de la lutte contre les 
infections et de la sécurité des patients, éducation à la santé publique et prise en charge des patients nécessiteux 
atteints d’affections hépatiques chroniques en tant qu’intervention sanitaire visant à réduire la pauvreté.




Hepatitis B virus (HBV) and hepatitis 
C virus (HCV) infections contribute 
to the global public health threats con-
fronting most developing countries, 
where health care systems lack the 
safety measures necessary to avert the 
risks of infection and public awareness 
about the modes of transmission is insuf-
ficient [1–3]. A large number of HBV 
and HCV studies have been carried out 
in Pakistan over the past two decades, 
restricted to clinical and hospital-based 
settings, blood bank institutions and 
small communities that could not val-
idly demonstrate the distribution of 
HBV and HCV in the general popula-
tion, though corroborating the exist-
ence of a high burden of chronic liver 
disease (CLD) in the country [4–7]. 
Since 1994, the World Health Or-
ganization (WHO) has worked with 
the Federal Ministry of Health substan-
tiating the urgency of adding hepatitis B 
vaccine to the roster of the national Ex-
panded Programme on Immunization 
(EPI) and of its provision to all newborn 
children in order to build a nationwide 
lifelong immunity against HBV and 
eliminate the burden of HBV-related 
CLD, including primary hepatocellular 
carcinoma. This recommendation was 
outlined in 1992 by WHO, with the 
goal of integrating hepatitis B vaccine 
into routine EPI by 1997 [8,9].
This aspiration was realized in 2002, 
through the financial support of the 
Global Alliance for Vaccines and Im-
munization (GAVI Alliance) and with 
WHO technical support, leading to 
the procurement of HBV vaccines for 
over 4 million newborns annually. This 
arrangement was sustained until 2008, 
when the pentavalent diphtheria–teta-
nus–pertussis–hepatitis B–Haemophil-
us influenzae type b (DTP–HepB–Hib) 
vaccine cofinancing mechanism was 
introduced. 
However, in a populous nation like 
Pakistan, the need for additional preven-
tive interventions and the management 
of a large pool of vulnerable patients 
with HBV- and HCV-related CLD re-
quired a national hepatitis B and C con-
trol programme with a preventive and 
curative scope of implementation. The 
high prevalence of HCV detected by 
multiple cross-sectional studies added 
to the alarm, as it is known that over 80% 
of HCV-infected individuals progress 
into CLD [1,10]. In 2004, the Ministry 
of Health developed the first project 
document of a national hepatitis control 
programme with federal funding, tech-
nically supported by WHO. This land-
mark was substantiated in 2005 when 
the national exchequer earmarked a 
5-year budgetary allocation of Rs 2.594 
billion, then equivalent to US$ 43 mil-
lion. The launching of the programme 
was facilitated by the strong political 
support, the growing public concern and 
the call for action resonated by profes-
sional groups, civil society organizations 
and the media, to contain an impending 
public health disaster. The programme 
scope included: vaccination of high-
risk groups; safety of blood and blood 
products; safe injections and invasive 
devices; hospital waste management; 
behavioural change communication 
and hospital-based surveillance. 
To substantiate the high burden 
of HBV and HCV infections and in-
fluence the government planning and 
financing institutions to offer a tangible, 
long-term budgetary outlay, there was a 
need to undertake a nationwide HBV 
and HCV survey that would guide the 
planning and implementation of hepa-
titis prevention and control interven-
tions. This paper reports the findings of 
this survey, which generated credible 
and representative national data about 
the high prevalence of HBV and HCV 
infections, and established the basis for 
future national control interventions 
and outcome evaluations.
Methods
The survey was conducted in urban 
and rural areas of all four provinces and 
territories of Pakistan, excluding the 
Federally Administered Tribal Areas 
and a few other security-compromised 
areas, cumulatively accounting for 
about 3% of the total population. The 
applied sampling frame was designed by 
the Federal Bureau of Statistics and clas-
sified cities and towns into well-defined 
enumeration blocks with 200–250 
households each, based on the 1998 
census population update carried out in 
2004 for urban settings; for rural areas 
the 1998 census data were applied as no 
similar update was available. 
These enumeration blocks and vil-
lages constituted the primary sampling 
units (PSUs), representing urban and 
rural areas, respectively. The PSUs were 
further specified for a group of 14 large 
mega-cities, each forming a separate 
structure that was further subdivided 
into low-, middle- and high-income 
groups, based on earlier data collected 
from these enumeration blocks. The 
remaining urban areas constituted one 
structure labelled “the other urban ar-
eas”, while the rural area of each district 
of the four provinces was considered 
as a separate structure, except in the 
sparsely populated province of Balo-
chistan, where the provincial adminis-
trative divisions each aggregating several 
districts were considered as the unit for 
the stratum. 
Considering the characteristics 
of the variables to be estimated, the 
population distribution and available re-
sources, 7000 sample households were 
considered necessary to attain reliable 
estimates of HBV and HCV prevalence 
for national and provincial levels and 
indicative data about districts. Sample 
households were drawn from 350 PSUs, 
138 urban and 212 rural. Relatively 
more PSUs were drawn from urban ar-
eas to account for their socioeconomic 
diversity. In the sample selection, urban 
enumeration blocks and villages were 
selected as PSUs, based on the “prob-
ability proportional to size” sampling 
method. Subsequently, households 
within PSUs were selected with equal 
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probability using a systematic sampling 
technique with random start. Thus 3500 
households were selected from Pun-
jab province; 1560 from Sindh; 1100 
from Khyber Pakhtunkhwa, formerly 
the North Western Frontier Province; 
and 840 from Balochistan. An average 
family size was 6.5 persons. For sam-
ple testing for hepatitis B and hepatitis 
C, rapid tests were used which were 
enzyme-linked immunosorbent assay 
(ELISA) compared, before being pro-
cured [Abbott Determine™ for hepatitis 
B surface antigen (HBsAg), Advanced 
Quality™ One Step HCV Test (Bionike 
Inc.) for anti-HCV).
A consent form to be completed 
by each family head, a family form, an 
individual form and a report form for 
feedback of results were prepared. An 
information brochure was produced to 
brief families about the objectives of the 
study. A referral form was also prepared 
for those needing further medical inves-
tigations. All forms were translated into 
the national language Urdu for easy field 
application and were field tested prior 
to survey implementation for validation 
and fine tuning. All testing surveyors 
were laboratory technicians who were 
further trained on how to share the 
information brochure with the fam-
ily head, explain the survey objectives 
and obtain consent for sampling family 
members, either by signing a consent 
form or through a thumb impression, 
in the presence of at least two fam-
ily members. The laboratory technician 
surveyors were trained on how to run 
HBV and HCV rapid tests using whole 
blood, and on how to mark names on 
the devices and on storage gel tubes 
where the PSU code, house number 
and person’s number and name were 
to be recorded. The tested blood kit 
devices, once checked, were pasted on 
the individual report forms to keep a 
record, while the reports were written 
on the back of individual forms to en-
sure that, if devices were lost, the written 
report remained. Blood was collected in 
gel tubes and serum was separated and 
stored for further testing. 
Hepatitis B e antigen (HBeAg) was 
tested on all HBsAg-positive sera that 
were stored for future use using the 
chemiluminescence method, carbonyl-
metalloimmunoassay.
To access targeted PSUs and 
households to be tested, survey teams 
contacted local health authorities and 
Federal Bureau of Statistics staff, who 
provided names of the households, eas-
ing identification of the correct houses. 
At the household level, blood tests were 
run in a row on all individuals, rapid 
tests carried out and results provided 
before leaving the house within 15–20 
minutes.
The house was marked after com-
pleting the survey. The teams were to 
visit all 20 houses of a PSU and seek 
the help of the local statistical office for 
replacement in the case of refusal or 
absence of family members. The Paki-
stan Medical Research Council closely 
monitored the work of the survey teams, 
assessing the accuracy of their access to 
the selected PSUs and contact with the 
identified households, and confirming 
that tests had been carried out. Any 
operational inconsistencies observed 
were then rectified to sustain the validity 
of the survey implementation. 
The survey commenced in July 
2007 and was completed in May 2008. 
The testing results were recorded using 
SPSS, version 13.0 and subsequently 
analysed. Statistical differences were 
estimated using the chi-square test, the 
odds ratio (OR) and 95% confidence 
interval (CI) measures. The data were 
disaggregated by province and district, 
although the district data were not ro-
bust, thus allowing conservative infer-
ences at that level. 
Results
This nationwide community survey 
was concluded in 11 months and was 
successful in reaching out to 96% of 
families and individuals selected from 
the 350 PSUs outlined in the study 
sample size. The non-tested 4% were 
due to migration, non-availability of the 
household members at the time of the 
visit, or refusals. 
Of the families in the sample, 87.6% 
owned their residential homes. Of the 
7000 houses visited, 32.0% were made 
of mud, 45.4% were made of bricks and 
plastered walls, 19.3% were of semi-solid 
material, while 3.3% of the houses were 
well-furnished modern constructions, 
indicating the wide socioeconomic di-
versity of the tested population. 
Piped drinking water was available 
in 52.7% of the houses; 21.8% of the 
families obtained water from nearby 
public taps; 9.7% used well water; 5% 
fetched water from a spring, pond or 
river; and 10.8% received water through 
tankers, or mule or donkey carts. 
Sanitation conditions varied: 26.5% 
did not have any toilet facilities at home; 
18.5% used pit latrines; and 55% had 
flush toilets. 
Excluding preschool children, 44.4% 
of screened individuals were illiterate, 
while 17% had education below the pri-
mary level; of the remaining individuals 
who had completed primary education, 
2% had completed 10 years of schooling 
and only 1% had graduate education. 
Of the tested adult populations 
41.4% were housewives or home-based 
self-employed, 25.5% were students, 
15.5% were employed at private or pub-
lic sector institutions, while the rest were 
unskilled workers. 
A history of jaundice was recalled 
by 3% of screened individuals, while 3% 
reported having one family member 
who suffered from liver disease. The 
screened families also reported 496 
family members who had died from 
liver disease. In the study population, 
the overall prevalence of HBsAg was 
2.5%, while anti-HCV prevalence was 
4.8%. 
Table 1 illustrates HBsAg and 
anti-HCV prevalence in the study 
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population, disaggregated by gender. 
Prevalence of anti-HCV did not show 
any gender difference, while HBsAg 
prevalence was significantly higher in 
males (OR = 1.48; 95% CI: 1.31–1.67). 
Table 1 Prevalence of hepatitis B surface antigen (HBsAg) and antibody to the 
hepatitis C virus (anti-HCV) by sex
Sex No. of subjects HBsAg positive Anti-HCV positive
No. (%) OR (95% CI) No. (%) OR (95% CI)
Female 22 599 447 (2.0) 1 1 090 (4.8) 1
Male 24 444 709 (2.9) 1.48 (1.31–1.67) 1 204 (4.9) 1.02 (0.94–1.11)
Total 47 043 1 156 (2.5) 2 294 (4.8)
CI = confidence interval; OR = odds ratio.
Table 2 Prevalence and factors associated with hepatitis B surface antigen (HBsAg) in Pakistan by age, marital status and 
history of injection use
Variable Males Females Total 
No. (%) OR (95%CI) No. (%) OR (95% CI) No.(%) OR (95% CI)
Age (years)
< 5 33 (1.6) 1 20 (1.0) 1 53 (1.3) 1
5–19 198 (2.1) 1.33 (0.90–1.96) 131 (1.5) 1.56 (0.95–2.57) 329 (1.8) 1.42 (1.05–1.92)
20–29 104 (2.4) 1.55 (1.03–2.35) 88 (2.1) 2.17 (1.30–3.64) 192 (2.2) 1.79 (1.30–2.46)
30–39 106 (3.7) 2.45 (1.63–3.72) 81 (2.8) 2.91 (1.74–4.91) 187 (3.2) 2.61 (1.90–3.60)
40–49 104 (4.5) 2.97 (1.97–4.50) 63 (3.0) 3.11 (1.83–5.34) 167 (3.8) 3.04 (2.20–4.20)
50–59 82 (5.5) 3.70 (2.41–5.68) 34 (2.6) 2.72 (1.51–4.92) 116 (4.1) 3.37 (2.40–4.75)
≥ 60 82 (5.0) 3.32 (2.16–5.10) 30 (2.7) 2.79 (1.53–5.13) 112 (4.0) 3.28 (2.33–4.62)
Total 709 (3.0) 447 (2.0) 1 156 (2.5)
Marital status (20–49 
years)
Never married 67 (1.9) 1 36 (1.7) 1 103 (1.8) 1
Married 245 (4.2) 2.32 (1.75–3.09) 193 (2.8) 1.70 (1.70–2.47) 438 (3.4) 1.96 (1.57–2.45)
Divorced/separated/
widowed 2 (2.7) 1.49 (0.0–6.3) 3 (1.5) 0.88 (0.27–2.84) 5 (1.8) 1.01 (0.36–2.59)
Total 314 (3.3) 232 (2.5) 546 (2.9)
No. of intramuscular 
injections 
None 111 (1.9) 1 87 (1.7) 1 198 (1.8) 1
< 5 359 (3.1) 1.68 (1.35–2.09) 215 (2.0) 1.13 (0.87–1.47) 574 (2.5) 1.42 (1.20–1.68)
5–10 177 (3.3) 1.83 (1.43–2.34) 114 (2.2) 1.87 (1.54–2.26) 291 (2.8) 1.55 (1.29–1.81)
> 10 62 (4.4) 2.43 (1.75–3.37) 31 (2.0) 1.17 (0.76–1.80) 93 (3.2) 1.78 (1.38–2.30)
Total 709 (2.9) 447 (2.0) 1 156 (2.5)
Types of syringes
None 115 (1.9) 1 83 (1.7) 1 198 (1.8) 1
New disposable 201 (2.5) 1.35 (1.06–1.71) 124 (1.6) 0.96 (0.72–1.29) 325 (2.1) 1.16 (0.97–1.39)
Re-used syringes 332 (3.7) 1.99 (1.60–2.49) 206 (2.4) 1.40 (1.08–1.83) 538 (3.0) 1.71 (1.44–2.02)
Don’t know 65 (4.6) 2.48 (1.80–3.42) 30 (2.2) 1.30 (0.83–2.02) 95 (3.4) 1.92 (1.48–2.47)
Total 706 (2.9) 450 (2.0) 1 156 (2.5)
CI = confidence interval; OR = odds ratio.
Table 2 shows HBsAg prevalence 
disaggregated by age, gender, marital 
status and history of injection use. The 
data illustrate age- and gender-related 
differences with a linear trend in the 
20 years and above age and gender 
strata until the 40–49 years age group 
(P < 0.01). No difference in HBsAg was 
found between the two youngest age 
categories or between the 40–49 years 
age group and higher age categories. 
Currently married individuals had signif-
icantly higher HBsAg positivity relative 
to those having no history of marriage 
(OR = 1.96; 95% CI: 1.57–2.45). 
Males with a history of injection use 
had significantly higher HBsAg preva-
lence relative to those not reporting 
injection use; this was true for females 
only when comparing those with 5–10 
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injections with non-users. Males using 
disposable syringes had significantly 
higher HBsAg prevalence relative to 
non-injection users, while this was not 
found among females. Likewise, no 
significant difference was found in HB-
sAg prevalence between females with 
lesser numbers of injections relative to 
those with higher numbers, while such 
a difference was significant for males 
with 10 or more injections relative to 
those with less than five. Table 3 illus-
trates prevalence of anti-HCV, disag-
gregated by age, gender, marital status 
and injection use. A significant increase 
in anti-HCV prevalence was observed 
distinctly in both genders of all age cat-
egories relative to the two youngest age 
groups. The most prominent increase in 
HCV infection rate was found among 
those aged between 20 and 49 years 
of age (P < 0.01). However, no anti-
HCV gender-based differences were 
found. Individuals with history of mar-
riage had significantly higher anti-HCV 
prevalence compared with those with 
no history of marriage (OR = 2.01; 95% 
CI: 1.72–2.34). 
With regard to injection use, anti-
HCV prevalence was significantly 
higher among users of any number of 
injections in both genders relative to 
non-users, while a similar difference 
was found in both genders between the 
different gradients of injection users. 
Anti-HCV was also significantly higher 
among persons exposed to reused sy-
ringes relative to those with no history 
of injection use, while no difference was 
found between non-users and those 
using new disposable syringes. 
Overall HBeAg positivity in the 
HBsAg-positive cohort was 14.5%. 
When HBeAg positivity in the study 
population was disaggregated by prov-
ince, Khyber Pakhtunkhwa had a lower 
HBeAg prevalence (8.5%); however, 
Table 3 Prevalence and factors associated with antibody to the hepatitis C virus (anti-HCV) in Pakistan by age, marital status 
and history of injection use
Variable Males Females Total
No. (%) OR (95 %CI) No. (%) OR (95% CI) No. (%) OR (95% CI)
Age (years) 
< 5 35 (1.7) 1 44 (2.1)1 1 79 (1.6) 1
5–19 192 (2.0) 1.21 (0.83–1.77) 187 (2.1) 1.00 (0.71–1.42) 379 (2.1) 1.09 (0.85–1.41)
20–29 170 (3.9) 2.43 (1.66–3.57) 205 (4.8) 2.33 (1.66–3.29) 375 (4.4) 2.38 (1.85–3.06)
30–39 204 (7.2) 4.62 (3.17–6.75) 247 (8.4) 4.23 (3.02–5.94) 451 (7.8) 4.41 (3.44–5.66)
40–49 261 (11.3) 7.56 (5.22–11.0) 182 (8.5) 4.29 (3.03–6.08) 443 (9.9) 5.75 (4.48–7.39)
50–59 162 (10.9) 7.29 (4.96–10.77) 128 (9.7) 4.96 (3.45–7.15) 290 (10.4 6.01 (4.63–7.81)
≥ 60 180 (10.9) 7.31 (4.99–10.76) 97 (8.6) 4.32 (2.96–6.32) 277 (10.0) 5.76 (4.43–7.50)
Total 1 204 (4.9) 1 090 (4.8) 2 294 (4.9)
Marital status (20–49 
years) 
Never married 139 (3.9) 1 80 (3.7) 1 219 (3.8) 1
Married 403 (6.9) 1.86 (1.52–2.28) 532 (7.7) 2.17 (1.70–2.78) 935 (7.3) 2.01 (1.72–2.34)
Divorced/separated/
widowed 5 (3.6) 0.93 (0.33–2.40) 20 (9.8) 2.82 (1.63–4.83) 25 (7.2) 1.99 (1.26–3.11)
Total 547 (5.7) 632 (6.7) 1 179 (6.2)
No. of intramuscular 
injections
None 227 (3.8) 1 175 (3.5) 1 402 (3.7) 1
< 5 550 (4.7) 1.25 (1.07–1.47) 457 (4.2) 1.20 (1.0–1.44) 1 007 (4.5) 1.23 (1.09–1.38)
5–10 312 (5.9) 1.58 (1.33–1.89) 329 (6.4) 1.87 (1.54–2.26) 641 (6.1) 1.71 (1.50–1.95)
> 10 115 (8.1) 2.25 (1.77–2.86) 129 (8.4) 2.54 (1.99–3.23) 244 (8.3) 2.38 (2.01–2.82)
Total 1 204 (4.9) 1 090 (4.8) 2 294 (4.9)
Types of syringes
None 227 (3.8) 1 175 (3.5) 1 402 (3.7) 1
New disposable 300 (3.7) 0.99 (0.83–1.18) 252 (3.3) 0.95 (0.78–1.16) 552 (3.5) 0.97 (0.85–1.11)
Re-used syringe 615 (6.8) 1.87 (1.59–2.19) 583 (6.7) 1.98 (1.66–2.36) 1 198 (6.8) 1.91 (1.70–2.15)
Don’t know 62 (4.3) 1.15 (0.85–1.55) 80 (5.9) 1.71 (1.29–2.27) 142 (5.1) 1.41(1.15–1.72)
Total 1 204 (4.9) 1 090 (4.8) 2 305 (4.9)
CI = confidence interval; OR = odds ratio.
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the detected interprovincial differences 
were not significant. 
Table 4 illustrates prevalence of HB-
sAg and anti-HCV in the study popu-
lation by housing structure, drinking 
water, sanitation, level of education and 
employment status. HBsAg was signifi-
cantly higher among pacca dwellers, and 
those using pit latrines or the open field, 
as well as in those with education less 
than the primary level, relative to those 
living in kacha houses, or using flush 
toilets or having higher education than 
the primary level respectively. HBsAg 
was also significantly higher among 
persons working in the government/
private sector and among daily wage-
earners, relative to those working from 
home. Contrary results were found for 
anti-HCV with regard to housing and 
sanitary facilities with a higher preva-
lence among those with relatively better 
facilities, while having a lower education 
level and working in the public/pri-
Table 4 Prevalence of hepatitis B surface antigen (HBsAg) and antibody to the 
hepatitis C virus (anti-HCV) by key social characteristics of the tested population
Variable HBsAg positive Anti-HCV positive
No. (%) OR (95% CI) No. (%) OR (95% CI)
Housing 
Kacha home 696 (2.2) 1 1 726 (5.4) 1
Pacca home 460 (3.1) 1.42 (1.25–1.60) 568 (3.8) 0.69 (0.62–0.76)
Drinking water
Piped water at home 604 (2.4) 1 1 425 (5.7) 1
Fetched water from 
 outside 552 (2.4) 0.98 (0.87–1.10) 869 (3.7) 0.64 (0.58–0.70)
Sanitation
Flush toilet available 555 (2.1) 1 1 318 (5.1) 1
Pit latrine at home or 
 going to field 601 (2.8) 1.33 (1.18–1.50) 976 (4.6) 0.90 (0.83–0.98)
Education
Primary and above 411 (2.3) 1 729 (4.0) 1
Below primary 745 (2.6) 1.15 (1.01–1.30) 1 565 (5.4) 1.38 (1.26–1.51) 
Employment
Self-employed working 
 from home 418 (2.1) 1 970 (5.0) 1
Working in government 
 private sector 230 (3.0) 1.43 (1.21–1.69) 485 (6.4) 1.31 (1.17–1.46)
Casual worker 51 (3.1) 1.47 (1.08–1.99) 99 (6.1) 1.23 (0.99–1.53)
CI = confidence interval; OR = odds ratio.
Table 5 Prevalence of hepatitis B surface antigen (HBsAg) and antibody to the hepatitis C virus (anti-HCV) by culture-related 
risk factors
Risk factor No. of 
subjects
HBsAg positive Anti-HCV positive 
No. (%) OR (95% CI) No. (%) OR (95% CI)
Shaving (male ≥ 20 years)
None 5 288 180 (3.4) 1 295 (5.6) 1
Home 1 983 73 (3.7) 1.1 (0.8–1.4) 149 (7.5) 1.4 (1.1–1.7)
Barber 5 419 244 (4.1) 1.5 (1.2–1.9) 532 (9.8) 1.8 (1.5–2.1)
Sharing tooth brush/miswak (≥ 5 
years)
No 2 364 1 083 (2.6) 1 2 173 (5.1) 1
Yes 476 20 (4.2) 1.6 (1.0–2.7) 41 (8.4) 1.6 (1.2–2.4)
Sharing cigarettes/hookah/bidi 
(adults ≥ 20 years)
No 23 027 698 (3.0) 1 1 676 (7.3) 1
Yes 1 373 75 (5.5) 1.8 (1.4–2.4) 158 (11.5) 1.7 (1.4–2.0)
Tattooing/acupuncture (≥ 5 years)
No 42 606 1 095 (2.6) 1 2 195 (5.2) 1
Yes 229 8 (3.5) 1.4 (0.6–2.8) 19 (8.3) 1.6 (1.0–2.7)
Ear/nose piercing (female ≥ 5 years)
No 5 257 76 (1.5) 1 161 (3.1) 1
Yes 15 141 351 (2.3) 1.6 (1.2–2.1) 886 (5.8) 2.0 (1.7–2.4)
History of surgery
No 44 697 1 083 (2.4) 1 2 058 (4.6) 1
Yes 2 346 73 (3.1) 1.3 (1.0–1.2) 236 (10.1) 2.3 (2.0–2.7)
CI = confidence interval; OR = odds ratio.
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vate sector was associated with a higher 
exposure to HCV infection. 
Table 5 illustrates prevalence of HB-
sAg and anti-HCV by exposure to several 
risk factors. In males aged 20 years and 
over, HBsAg prevalence was significantly 
higher among those who were shaved 
at a barber shop, relative to those who 
shaved at home or who did not shave 
at all, while no difference was found be-
tween those who shaved at home, relative 
to those who did not shave at all. Anti-
HCV prevalence was significantly higher 
among those shaving either at barber 
shops or at home compared with those 
who did not shave at all. Both HBsAg and 
HCV were more prevalent among those 
who shared tooth brush/miswak or ciga-
rettes/hookah and bidi, or had pierced 
ears or nose, or had a history of surgery. 
Anti-HCV was also significantly more 
prevalent among those with a history of 
tattooing and acupuncture, relative to 
those who did not. 
Figure 1 illustrates the differences 
in prevalence among the provinces and 
districts. While overall prevalence of 
HCV was 4.8%, the Punjab province 
had significantly higher prevalence 
(6.7%) relative to Sindh (5.0%), which 
in turn had significantly higher anti-
HCV prevalence when compared to 
Balochistan (1.5%) or Khyber Pa-
khtunkhwa (1.1%).
Overall prevalence of HBsAg was 
2.5%, and Balochistan had the high-
est prevalence (4.3%) relative to Sindh 
(2.5%) and Punjab (2.4%), which in turn 
had significantly higher prevalence in 
comparison with Khyber Pakhtunkhwa 
(1.3%).
Discussion
The HBV and HCV epidemiological 
studies carried out in Pakistan during 
past decades had limited geographical 
scope, different time frames, applied 
diverse methodologies, and predomi-
nantly focused on hospital and high-
risk population groups [4–7,11]. 
Despite these considerable diversities 
and limitations, the studies supported 
the presence of high HBV and HCV en-
demicity in Pakistan, promulgating the 
high burden these viral infections pose 
to populations’ health. These studies 
determined HBsAg prevalence to range 
from 2.6% to 3.5%, while anti-HCV 
prevalence ranged from 3.3% to 5.3%, 
although lower HBV prevalence was 
reported from blood donors [12–14]. 
Among CLD patients, 10%–46% had 
HBV infections and 40%–86% had 
anti-HCV [15–18]. 
The current study has corroborated 
the above reported high endemicity of 
HBV and HCV infections in the country, 
where the overall HBsAg and anti-HCV 
cumulative prevalence was 7.6%, reflect-
ing a population pool of about 13 million 
being HBV and HCV chronic carriers. 
These findings are consistent with a cur-
rent or imminent high burden of liver 
disease where 25% of the HBsAg and 
80%–85% of the anti-HCV positive indi-
viduals may later progress to CLD [1,8]. 
The association of HBV infection 
with increased age, marital status and 
Figure 1 Maps illustrating the geographical burden of hepatitis B and C viral 
infections in Pakistan. FANA = Federal Administered Northern Areas; FATA = 
Federally Administered Tribal Areas; NWFP = North West Frontier Area
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exposure to a series of risk factors in-
cluding lesser education, outdoor 
employment, poor sanitation, shaving 
at the barber, ear/nose piercing and his-
tory of surgery corroborates the diverse 
complementary sources of infection 
and the need for universal hepatitis B 
vaccination of all newborn infants and 
high-risk groups and other hepatitis 
control preventive interventions. How-
ever, the lower level of HBV infection in 
teenage groups in both sexes may reflect 
a lesser exposure at that age.
In 2000, Pakistan introduced the 
monovalent hepatitis B vaccine in the 
national EPI and replaced it in 2008 with 
the pentavalent vaccine where hepatitis 
B vaccine is jointly administered with 
diphtheria, tetanus, pertussis and Hae-
mophilus influenzae B vaccines, reducing 
the number of child vaccination con-
tacts to improve vaccine acceptability 
and wastage control. Unfortunately, the 
current performance of the EPI shows 
that a large number of newborns miss 
the opportunity of accessing these regu-
larly procured vaccines, reflecting the 
unnecessary avoidable harm to which 
many children are exposed. 
However, the study could not ex-
clude the importance of vertical trans-
mission, a matter requiring a focused 
study to evaluate the need for corre-
sponding preventive interventions. The 
higher prevalence of HBV among mar-
ried individuals may reflect the potential 
of sexual transmission, this being an 
epidemiologically recognized mode of 
infection, mandating public education 
about this risk of infection transition 
[19]. 
The higher association of HBV infec-
tion with lower socioeconomic condi-
tions and exposure to related risk factors 
categorizes hepatitis B as a disease of 
poverty, where the aforementioned 
lower immunization coverage in chil-
dren residing in underprivileged areas 
raises concerns of inequity. Moreover, 
these finding give directions for ensur-
ing the vaccination of high-risk groups, 
especially the health workforce, and 
promotion of infection-control safety 
measures when undertaking traditional 
practices entailing the use of invasive 
devices. 
The incremental age-related preva-
lence of HCV infection reflects increased 
exposure to high-risk practices such as 
the widespread reuse of syringes and a 
range of high risky traditional practices. 
These behaviours need to be controlled, 
both among health providers and in the 
community at large, as out of 95% of the 
globally used injections administered 
for therapeutic purposes, 50% were 
unsafe while 80% were unnecessary 
[20,21]. This observation is strongly 
substantiated by the evident correlation 
between anti-HCV prevalence and the 
reuse of syringes and frequency of injec-
tion use. High community exposure to 
unsafe injections may also account for 
the observed lack of gender variation in 
HCV prevalence. These findings call for 
the promotion of a nationwide injection 
safety programme in all health facilities 
where related guidelines become an 
integral part of a patient safety inter-
vention with adherence to the funda-
mentals of quality of care. The common 
use of multidose vials also needs to be 
discouraged and practice by quacks pre-
vented through the promotion of public 
awareness against these risky though 
traditional practices. 
The corroborated greater HBV and 
HCV risk of infection associated with 
the history of surgery substantiates the 
need for improving the safety of surgical 
care. While transmission of HBV can 
be tangibly controlled in a few decades 
through an effective universal vaccina-
tion of the identified target population 
groups coupled with public education 
and behaviour change communica-
tion, for HCV, where vaccination is 
not an option, public education and 
advocacy control interventions must 
be supplemented by the universal use 
of auto-disable syringes that should 
replace reusable disposable syringes in 
the country. Health authorities may also 
expedite the introduction of injection 
and patient safety measures in all health 
facilities and the setting of strategic 
policies that curtail the use of multidose 
vials, including those obtained from vet-
erinary sources and misused by quacks. 
Moreover, the currently pursued 
nationwide free treatment for under-
privileged CLD patients needs to be 
sustained, as this constitutes a health 
intervention mitigating poverty, gener-
ating public support for the programme 
and impacting on the quality of life of 
these patients. 
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